---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-051847"
form_type: "8-K"
ticker: "REPL"
cik: "0001737953"
company_name: "Replimune Group, Inc."
filed_at: "2025-05-22T23:59:59+00:00"
generated_at: "2026-05-20T18:29:12.727624+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Replimune Q4 net loss $74.1M; RP1 BLA on track for July 22 PDUFA

## Summary
- Net loss Q4 $74.1M, FY $247.3M; cash $483.8M, runway into Q4 2026 excluding revenue.
- BLA for RP1+nivolumab in advanced melanoma on schedule; PDUFA July 22, 2025; no advisory committee.
- Commercial infrastructure fully built and ready for launch; distribution channels established.
- R&D Q4 $54.0M (+27% YoY); SG&A Q4 $25.4M (+57% YoY) driven by pre-launch scaling.
- Investor day June 24; confirmatory Phase 3 IGNYTE-3 enrolling 400 patients globally.

## SEC filing metadata
- accession: 0001104659-25-051847
- form_type: 8-K
- ticker: REPL
- cik: 0001737953
- company_name: Replimune Group, Inc.
- filed_at: 2025-05-22T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737953/000110465925051847/0001104659-25-051847-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737953/000110465925051847/tm2515645d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-051847
- JSON: https://secwatch.observer/filing/0001104659-25-051847.json
- Plain text: https://secwatch.observer/filing/0001104659-25-051847.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.